

Study ID	Intervention	No. randomised	Median age (years)	Male (%)	Disease stage		Histology		PS (%)	
					IIIA (%)	IIIB (%)	Squamous cell carcinoma (%)	Adenocarcinoma (%)		
Jeremic 2001 ⁶³	CTX + RT days 1–5	99	59	64	52	48	NR	NR	KPS	50 = 8, 60 = 9, 70 = 11, 80 = 24, 90 = 30, 100 = 17
	CTX + RT days 1–7	99	59	67	54	46	NR	NR	KPS	50 = 8, 60 = 9, 70 = 9, 80 = 23, 90 = 29, 100 = 21
Komaki 2002 ⁵⁰	CTX → CTX + RT	NR	NR	72	35	64	43	30	KPS	70–80 = 27, 90–100 = 73
	CTX + (HFX)RT	NR	NR	59	33	66	40	35	KPS	70–80 = 23, 90–100 = 77
Schild 2002 ⁶²	CTX + RT (2×daily)	121	64	62	51	49	35	NR	ECOG	0 = 49, 1 = 51
	CTX + RT (4×daily)	125	64	62	54	46	38	NR	ECOG	0 = 50, 1 = 50
Vokes 2002 ⁴⁷	CTX → CTX + RT	NR	62	66	63	37	29	34	CALGB	0 = 53, 1 = 47
	CTX → CTX + RT	NR	64	66	52	48	29	45	CALGB	0 = 53, 1 = 47
	CTX → CTX + RT	NR	58	76	40	60	42	33	CALGB	0 = 51, 1 = 49
Zatloukal 2004 ⁵¹	CTX + RT	52	62	63	15	85	46	23	WHO	0 = 29, 1 = 63, 2 = 8
	CTX → RT	50	61	72	14	86	44	30	WHO	0 = 32, 1 = 64, 2 = 4
Belani 2005 ⁵²	CTX → RT	97	NR	67	35	62	42	35	KPS	70 = 8, 80–100 = 92
	CTX → CTX + RT	80	NR	73	36	64	32	34	KPS	70 = 7, 80–100 = 93
	CTX + RT → CTX	99	NR	67	38	62	40	35	KPS	70 = 2, 80–100 = 98

Study ID	Intervention	No. randomised	Median age (years)	Male (%)	Disease stage		Histology		PS (%)	
					IIIA (%)	IIIB (%)	Squamous cell carcinoma (%)	Adenocarcinoma (%)		
Fournel 2005 ⁴⁹	CTX → RT	106	56	90	18	80	55	30	ECOG	0 = 56, 1 = 45
	CTX + RT → CTX	106	57	85	88	67	60	23	ECOG	0 = 51, 1 = 49
Reinfuss 2005 ⁴⁶	CTX → RT	89	NR	72	33	67	69	31	KPS	70–80 = 84, 90 = 16
	CTX + RT	84	NR	71	33	67	67	32	KPS	70–80 = 85, 90 = 15
Dasgupta 2006 ⁵⁶	CTX → RT	35	58	NR	69	31	63	31	KPS	60 = 3, 70 = 31, 80 = 51, 90 = 14
	CTX + RT	36	57	NR	67	33	50	33	KPS	60 = 6, 70 = 22, 80 = 56, 90 = 17
Gouda 2006 ⁵⁹	CTX → CTX + RT	20	61	90	30	70	55	35	ECOG	0 = 15, 1 = 85
	CTX + RT	20	62	75	15	85	70	25	ECOG	0 = 5, 1 = 95
Belderbos 2007 ⁵⁴	CTX → RT	78	64	100	45	47	40	32	WHO	0 = 42, 1 = 58
	CTX + RT	80	62	93	30	64	40	24	WHO	0 = 44, 1 = 56
Vokes 2007 ⁴⁸	CTX + RT	182	63	69	48	46	NR	NR	CALGB	0 = 45, 1 = 52
	CTX → CTX + RT	184	64	63	49	48	NR	NR	CALGB	0 = 44, 1 = 56
Liu 2008 ⁵³	Low-dose weekly CTX (DOC) + RT (3D conformal) → CTX (DOC + CIS)	22	53	73	45	55	36	50	ECOG	0 = 36, 1 = 64
	Systemic CTX + RT (3D conformal) → CTX (DOC + CIS)	22	60	82	36	64	55	36	ECOG	0 = 23, 1 = 77
Socinski 2008 ⁵⁵	CTX → RT + CTX	43	62	74	38	38	36	40	ECOG	0 = 48, 1 = 52
	CTX → RT + CTX	26	58	77	38	62	35	27	ECOG	0 = 38, 1 = 62

Study ID	Intervention	No. randomised	Median age (years)	Male (%)	Disease stage		Histology		PS (%)	
					IIIA (%)	IIIB (%)	Squamous cell carcinoma (%)	Adenocarcinoma (%)		
Berghmans 2009 ⁴⁵	CTX + RT → CTX	26	55	86	19	76	33	43	KPS	60–70 = 14, 80–100 = 86
	CTX → CTX + RT	29	61	89	32	68	29	43	KPS	60–70 = 7, 80–100 = 93
Crvenkova 2009 ⁵⁷	CTX → RT	NR	45	89	NR	NR	76	13	NS	0 = 62, 1 = 38
	CTX + RT → CTX	NR	40	88	NR	NR	55	25	NS	0 = 68, 1 = 32
Nyman 2009 ⁵⁸	CTX → CTX + accelerated RT	NR	63 (mean)	51	35	65	27	51	WHO	0 = 26, 1 = 22
	CTX → CTX daily + conventional RT	NR	63 (mean)	44	32	68	32	46	WHO	0 = 27, 1 = 22
	CTX → CTX weekly + conventional RT	NR	61 (mean)	60	35	65	35	44	WHO	0 = 27, 1 = 24
Zhu 2009 ⁶⁰	CTX + RT (3D conformal)	NR	60	75	NR	NR	43	52	NR	NR
	CTX → RT (3D conformal)	NR	59	76	NR	NR	40	52	NR	NR
Movsas 2010 ⁶¹	CTX + RT → CTX	32	59.5	53	16	81	50	38	ECOG	0 = 34, 1 = 66
	CTX + RT → CTX	32	59.5	81	34	59	53	30	ECOG	0 = 41, 1 = 59

HFX, hyperfractionated; NR, not reported.